Valeant Completes Acquisition Of Natur Produkt In Russia

Valeant Completes Acquisition Of Natur Produkt In Russia

MONTREAL , Feb. 1, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the completion of its acquisition of Natur Produkt International, JSC, a specialty pharmaceutical company in Russia , for approximately $163 million , plus adjustments for net debt and working capital. Natur Produkt has a significant presence in the over-the-counter (OTC) segment in several categories marketed under the umbrella brand, Natur Produkt. Key brands include AntiGrippin, a leading cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA brand names, leading sore throat remedies.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

SOURCE: Valeant Pharmaceuticals International, Inc.
Contact:

http://www.valeant.com

http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.